Equillium to Present at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Equillium, a clinical-stage biotech company, announced its participation in the Jefferies Virtual Healthcare Conference, scheduled for June 1-4, 2021. CEO Bruce Steel and Dr. Dolca Thomas will discuss ongoing clinical programs for itolizumab, targeting severe autoimmune disorders, including acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma. The presentation is set for June 2 at 11:00 AM ET, accessible via a live webcast on their website, with an archived replay available for 90 days.

LA JOLLA, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the Jefferies Virtual Healthcare Conference taking place June 1 – 4, 2021.

Bruce Steel, Equillium’s chief executive officer, and Dolca Thomas, M.D., Equillium’s executive vice president of research and development and chief medical officer, will review each of the ongoing clinical programs in acute graft-versus-host disease, lupus/lupus nephritis and uncontrolled asthma. Mr. Steel, Dr. Thomas and other members of Equillium’s leadership team will be available for one-on-one meetings during the conference.

Date:	Wednesday, June 2, 2021
Time:	11:00 AM Eastern Time | 8:00 AM Pacific Time
Location:	Virtual Webcast

A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

For more information, visit www.equilliumbio.com.

Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
+1-619-302-4431
ir@equilliumbio.com

Media Contacts
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

When is Equillium presenting at the Jefferies Virtual Healthcare Conference?

Equillium is presenting on June 2, 2021, at 11:00 AM Eastern Time.

What is the main focus of Equillium's presentation at the conference?

Equillium's presentation will focus on ongoing clinical programs for itolizumab in treating severe autoimmune disorders.

Where can I watch Equillium's conference presentation?

The presentation will be available as a live webcast on Equillium's website under the 'Investors' section.

What conditions is itolizumab being developed to treat?

Itolizumab is being developed to treat acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma.

Is there an archive available for the Equillium presentation?

Yes, an archived replay of the presentation will be available for 90 days after the event.